Summary
Fotemustine (S 10036) is a new anti-tumor nitrosourea characterized by a phosphonoalanine carrier group coupled to the nitrosourea moiety, which potentially increases the cellular penetration of the drug. Using human tumor cell lines, the activity of S 10036 was compared with that of the more established nitrosoureas BCNU and CCNU. Growth-inhibiting effects were evaluated by the [3H]-thymidine incorporation test. In a panel of 12 human cancer cell lines [melanoma (4), ovary (2), head and neck (3), lung (1), bladder (1), breast (1)], the dose-response curves of S 10036 (0–100 μM) were similar to those obtained with equimolar concentrations of BCNU and CCNU; they indicated a moderately more marked effect for two and an equal effect for six melanoma cell lines with S 10036 as compared with BCNU. Moderate but significant synergistic combinations were obtained when S 10036 (0–80 μM) and CDDP (0–100 μM) or DTIC (250–6,500 μM) were combined in melanoma cell lines. In conclusion, the new nitrosourea S 10036 shows promising activity, particularly against human melanoma cell lines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alberts DS, Chen MS, Salmon SE (1980) Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. In: Salmon SE (ed) Cloning of human tumor stem cells. A. Liss, New York, p 351
Courdi A, Gioanni J, Lalanne CM, Fischel JL, Schneider M, Ettore F, Lambert JC (1983) Establishment, characterization and response to cytotoxic and radiation treatment of three human melanoma cell lines. In vitro 19:453
Drewinko B, Green C, Ti Li Loo (1976) Combination chemotherapy in vitro withcis-dichlorodiammineplatinum(II). Cancer Treat Rep 60:1619
Gioanni J, Courdi A, Lalanne CM, Fischel JL, Zanghellini E, Lambert JC, Ettore F, Namer M (1985) Establishment, characterization, chemosensitivity and radiosensitivity of two different cell lines derived from a human breast cancer biopsy. Cancer Res 45:1246
Gioanni J, Fischel JL, Lambert JC, Demard F, Mazeau C, Zanghellini E, Ettore F, Formento P, Chauvel P, Lalanne CM, Courdi A (1988) Two new human tumor cell lines derived from squamous cell carcinomas of the tongue. Establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol 24:1445
Khayat D, Lokiec F, Bizzari JP, Weil M, Meeus L, Sellami M, Rouesse J, Banzet P, Jacquillat (1987) Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. Cancer Res 47:6782
Khayat D, Bizzari JP, Frenay M, Naman H, Weil M, Goupil A, Namer M, Rouesse J, Banzet P, Jacquillat C (1988) Interim report of a phase II study of the new nitrosourea S 10036 in disseminated malignant melanoma. J Natl Cancer Inst 80: 1407
Meyn RE, Murray D (1984) Cell cycle effects of alkylating agents. Pharmacol Ther 24:147
Roed H, Vindelov LL, Spang-Thomsen M, Christensen IJ, Hansen HH (1987) In vitro evaluation of a new nitrosourea, TCNU, against human small-cell lung cancer cell lines. Cancer Chemother Pharmacol 19:315
Tapiero H, Catalin J, Biao-Yin M, Deloffre P, Lampidis TJ, Tew K, Rustum Y (1988) Cytoxicity, DNA cross links, strand breaks and DNA repair induced by a new nitrosourea (S 10036). Proc Am Assoc Cancer Res 29:503
Volm M, Kaufman M, Hinderer H, Goether J (1970) Schnellmethode zur Sensibilitätstestung malignen Tumoren. Klin Wochenschr 48:374
Williams CJ, Whitehouse JMA (1979) Cisplatinum, a new anticancer agent. Br Med J 1:1689
Workman P (1987) TCNU: a ray of hope for designer nitrosoureas? Eur J Cancer Clin Oncol 23:1823
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fischel, J.L., Formento, P., Etienne, M.C. et al. In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea. Cancer Chemother. Pharmacol. 25, 337–341 (1990). https://doi.org/10.1007/BF00686233
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686233